November 14, 2024) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage biotechnology company exploring new pathways towards a cancer-free future by using its INTASYL ® siRNA gene silencing ...

Researchers hope targeted alpha therapy — now undergoing clinical trials in Canada — will become the future of cancer treatment. This therapy seeks out and kills cancer cells without damaging healthy ...

Kebilidi is the first approved gene therapy that can be directly administered to the brain. Its OK secures a priority review ...

An international, Phase III clinical trial led by investigators at Mass General Brigham could improve the treatment of a rare ...

At the 42nd Annual Chemotherapy Foundation Symposium, Erin Mulvey, MD, discussed the significant progress being made in the ...

Ivermectin is an antiparasitic agent, and its potential as an anticancer agent has recently attracted increasing attention.

Kenai Therapeutics, a biotechnology company leveraging induced pluripotent stem cell (iPSC) technology to discover and develop a platform of off-the-shelf neuron replacement therapies for neurological ...

chemotherapy and radiation therapy, researchers said in background notes. The trial patients all had undergone chemotherapy, ...

Kebilidi is delivered into the putamen - a part of the brain that is involved with learning, motor control and speech - and ...

San Francisco–based Ossium Health has carried out three transplants for cancer patients using stem cells from deceased donors ...

In a sense, the combination begins to awaken the cells to their purpose within the body. You might say the treatment acts as a template of what is normal for the ... with the Beat and then sent to the ...